Compositions and methods for cancer diagnosis and treatment
View Patent ↗The application relates to methods and compositions for the diagnosis, prevention, and treatment of tumors and cancers in mammals, for example, humans, utilizing the mir17-92 cluster. The application further relates to screening methods to identify compounds and reagents useful in cancer diagnosis, prevention, and therapy.
1. A method for decreasing the expression or activity of miR-19b in a cell from a B-cell malignancy, comprising contacting a cell from a B-cell malignancy with a nucleic acid compound that hybridizes to miR-19b, wherein the nucleic acid compound decreases the expression or activity of miR-19b, and wherein the nucleic acid compound is an antisense nucleic acid.
2. The method of claim 1 , wherein the nucleic acid compound comprises one or more modified backbone or base moieties.
3. The method of claim 2 , wherein the nucleic acid compound is resistant to endogenous nucleases.
4. The method of claim 2 , wherein the nucleic acid compound is stable in vivo.
5. The method of claim 1 , wherein the B-cell malignancy is a myc-induced B-cell malignancy.
6. The method of claim 1 , wherein the cell from the B-cell malignancy is a mouse cell.
7. The method of claim 1 , wherein the cell from the B-cell malignancy is a human cell.
8. The method of claim 1 , wherein the cell from the B-cell malignancy is in vitro.
9. The method of claim 1 , wherein the nucleic acid compound comprises SEQ ID NO: 11.
10. The method of claim 1 , further comprising contacting the cell from the B-cell malignancy with an antisense nucleic acid that hybridizes to miR-18.
11. The method of claim 1 , further comprising contacting the cell from the B-cell malignancy with a chemotherapeutic agent.
12. The method of claim 1 , further comprising contacting the cell from the B-cell malignancy with an anti-CD20 monoclonal antibody or an anti-CD22 antibody.
13. A method for decreasing the expression or activity of miR-18 in a cell from a B-cell malignancy, comprising contacting a cell from a B-cell malignancy with a nucleic acid compound that hybridizes to miR-18 wherein the nucleic acid compound decreases the expression or activity of miR-18, and wherein the nucleic acid compound is an antisense nucleic acid.
14. The method of claim 13 , wherein the nucleic acid compound comprises one or more modified backbone or base moieties.
15. The method of claim 14 , wherein the nucleic acid compound is resistant to endogenous nucleases.
16. The method of claim 14 , wherein the nucleic acid compound is stable in vivo.
17. The method of claim 13 , wherein the B-cell malignancy is a myc-induced B-cell malignancy.
18. The method of claim 13 , wherein the cell from the B-cell malignancy is a mouse cell.
19. The method of claim 13 , wherein the cell from the B-cell malignancy is a human cell.
20. The method of claim 13 , wherein the cell from the B-cell malignancy is in vitro.
21. The method of claim 13 , wherein the nucleic acid compound comprises SEQ ID NO: 12.
22. The method of claim 13 , further comprising contacting the cell from the B-cell malignancy with an antisense nucleic acid that hybridizes to mir-19b.
23. The method of claim 13 , further comprising contacting the cell from the B-cell malignancy with a chemotherapeutic agent.
24. The method of claim 13 , further comprising contacting the cell from the B-cell malignancy with an anti-CD20 monoclonal antibody or an anti-CD22 antibody.